Exposure–response relationship for ramucirumab from the randomized, double-blind, phase 3 REVEL trial (docetaxel versus docetaxel plus ramucirumab) in second-line treatment of metastatic non-small cell lung cancer
暂无分享,去创建一个
F. Cappuzzo | E. Smit | D. Ferry | A. Zimmermann | R. Cohen | Ling Gao | M. Reck | E. Garon | A. Melemed | P. Bidoli | M. Pérol | L. O’Brien | Pablo Lee